following a full submission
eluxadoline (Truberzi®) is not recommended for use within NHS Scotland.
Indication under review: in adults for the treatment of irritable bowel syndrome with diarrhoea (IBS-D).
Eluxadoline showed superiority over placebo in producing a composite response, which included abdominal pain response and stool consistency response, in patients with IBS-D.
The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Download detailed advice335KB (PDF)
- Medicine name:
- eluxadoline (Truberzi)
- SMC ID:
- in adults for the treatment of irritable bowel syndrome with diarrhoea (IBS-D).
- Pharmaceutical company
- Allergan Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Not recommended
- Date advice published
- 15 January 2018